Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

PPARgamma and atherosclerosis.

¹Département d'Athérosclérose - U.545 Inserm, Institut Pasteur de Lille, et Université de Lille2, Lille, France. bart.staels@pasteur-lille.fr

Current Medical Research and Opinion

|April 7, 2005

Summary

Thiazolidinediones, a type of medication for type 2 diabetes, demonstrate significant cardioprotective effects by improving endothelial function and reducing inflammation. These agents offer potential benefits against atherosclerosis and cardiovascular complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Increased 1-deoxysphingolipids caused by an altered plasma alanine to serine ratio are associated with metabolic dysfunction-associated steatotic liver disease (MASLD).

Metabolomics : Official journal of the Metabolomic Society·2025

Same author

Role of bile acid receptor FXR in development and function of brown adipose tissue.

Biochimica et biophysica acta. Molecular and cell biology of lipids·2022

Same author

[State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)].

Annales pharmaceutiques francaises·2022

Same author

Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.

Acta diabetologica·2020

Same author

Best Poster Award - Second Prize: Bile Acids as Novel Vascular Signalling Molecules and Therapeutic Target.

European cardiology·2020

Same author

Peroxisome Proliferator-Activated Receptor <i>γ</i> Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages.

PPAR research·2017

Area of Science:

Cardiovascular Science
Endocrinology
Pharmacology

Background:

Peroxisome proliferator-activated receptor (PPAR)gamma plays a crucial role in glucose homeostasis, endothelial function, and inflammation.
PPARgamma agonists, thiazolidinediones, are used to treat type 2 diabetes and show promise in preventing cardiovascular complications.
Emerging evidence suggests thiazolidinediones offer cardioprotective benefits throughout the stages of atherogenesis.

Purpose of the Study:

To review preclinical and clinical evidence on the cardiovascular benefits of thiazolidinediones.
To discuss the implications of these findings for clinical practice.

Main Methods:

Literature search of MEDLINE databases.
Review of preclinical (in vitro, animal models) and clinical studies.
Synthesis of evidence on thiazolidinedione effects on cardiovascular parameters.

Main Results:

Thiazolidinediones improve endothelial dysfunction.
They suppress chronic inflammatory processes in the vasculature.
Studies show reduced fatty streak formation, delayed plaque evolution, and enhanced plaque stabilization/regression.

Conclusions:

Thiazolidinediones exhibit potent anti-inflammatory and antithrombotic properties.
These agents can improve glycemic control in type 2 diabetes.
Thiazolidinediones hold potential for reducing long-term cardiovascular risk associated with atherosclerosis.

Related Experiment Videos